Stocks
Affimed Financial Statements (AFMD) |
||||||||||
| Affimedsmart-lab.ru | % | 2021 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 31.12.2021 | 31.03.2022 | 31.12.2022 | 23.03.2023 | 28.03.2024 | 30.09.2024 | ||||
| Currency | EUR | EUR | EUR | EUR | EUR | EUR | ||||
| Financial report URL | ||||||||||
| Revenue, € | ? | 40 366 000 | 40 366 000 | 41 353 000 | 41 353 000 | 8 275 000 | 877 000 | |||
| Operating Income, € | -64 030 000 | -64 030 000 | -88 119 000 | -88 119 000 | -106 661 000 | -70 206 000 | ||||
| EBITDA, € | ? | -64 006 000 | -64 006 000 | -86 637 000 | -81 473 000 | -102 380 000 | -65 530 000 | |||
| Net profit, € | ? | -57 523 000 | -57 523 000 | -86 004 000 | -86 004 000 | -105 938 000 | -69 970 000 | |||
| OCF, € | ? | -86 591 000 | -86 591 000 | -104 892 000 | -104 892 000 | -110 269 000 | -76 904 000 | |||
| CAPEX, € | ? | 3 850 000 | 3 850 000 | 696 000 | 696 000 | 3 729 000 | 534 000 | |||
| FCF, € | ? | -90 441 000 | -90 441 000 | -105 588 000 | -105 588 000 | -113 998 000 | -77 438 000 | |||
| Dividend payout, € | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, € | 105 706 000 | 105 706 000 | 130 889 000 | 130 889 000 | 114 936 000 | 74 616 000 | ||||
| Cost of production, € | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| R&D, € | 81 488 000 | 81 488 000 | 98 814 000 | 98 814 000 | 94 958 000 | 55 910 000 | ||||
| Interest expenses, € | 712 000 | 712 000 | 1 630 000 | 1 630 000 | 1 806 000 | 1 358 000 | ||||
| Assets, € | 225 135 000 | 225 135 000 | 200 512 000 | 200 512 000 | 97 157 000 | 39 959 000 | ||||
| Net Assets, € | ? | 135 951 000 | 135 951 000 | 152 915 000 | 152 915 000 | 57 807 000 | 17 195 000 | |||
| Debt, € | 18 691 000 | 18 691 000 | 18 189 000 | 18 189 000 | 19 351 000 | 12 889 000 | ||||
| Cash, € | 197 630 000 | 197 630 000 | 190 286 000 | 190 286 000 | 72 898 000 | 24 940 000 | ||||
| Net debt, € | -178 939 000 | -178 939 000 | -172 097 000 | -172 097 000 | -53 547 000 | -12 051 000 | ||||
| Ordinary share price, rub | 5.52 | 55.2 | 1.24 | 12.4 | 6.25 | 0.350 | ||||
| Number of ordinary shares, mln | 119 502 384 | 11 950 238 | 142 362 294 | 14 236 229 | 14 939 916 | 0.000 | ||||
| Market cap, € | 659 653 160 | 659 653 138 | 176 529 245 | 176 529 240 | 93 374 475 | 0.00 | ||||
| EV, € | ? | 480 714 160 | 480 714 138 | 4 432 245 | 4 432 240 | 39 827 475 | -12 051 000 | |||
| Book value, € | 134 344 000 | 134 344 000 | 152 857 000 | 152 857 000 | 57 782 000 | 17 195 000 | ||||
| EPS, rub | ? | -0.48 | -4.81 | -0.60 | -6.04 | -7.09 | ||||
| FCF/share, rub | -0.76 | -7.57 | -0.74 | -7.42 | -7.63 | |||||
| BV/share, rub | 1.12 | 11.2 | 1.07 | 10.7 | 3.87 | |||||
| EBITDA margin, % | ? | -158.6% | -158.6% | -209.5% | -197.0% | -1 237% | -7 472% | |||
| Net margin, % | ? | -142.5% | -142.5% | -208.0% | -208.0% | -1 280% | -7 978% | |||
| FCF yield, % | ? | -13.7% | -13.7% | -59.8% | -59.8% | -122.1% | 0.00% | |||
| ROE, % | ? | -42.3% | -42.3% | -56.2% | -56.2% | -183.3% | -406.9% | |||
| ROA, % | ? | -25.6% | -25.6% | -42.9% | -42.9% | -109.0% | -175.1% | |||
| P/E | ? | -11.5 | -11.5 | -2.05 | -2.05 | -0.88 | 0.00 | |||
| P/FCF | -7.29 | -7.29 | -1.67 | -1.67 | -0.82 | 0.00 | ||||
| P/S | ? | 16.3 | 16.3 | 4.27 | 4.27 | 11.3 | 0.00 | |||
| P/BV | ? | 4.91 | 4.91 | 1.15 | 1.15 | 1.62 | 0.00 | |||
| EV/EBITDA | ? | -7.51 | -7.51 | -0.05 | -0.05 | -0.39 | 0.18 | |||
| Debt/EBITDA | 2.80 | 2.80 | 1.99 | 2.11 | 0.52 | 0.18 | ||||
| R&D/CAPEX, % | 2 117% | 2 117% | 14 197% | 14 197% | 2 546% | 10 470% | ||||
| CAPEX/Revenue, % | 9.54% | 9.54% | 1.68% | 1.68% | 45.1% | 60.9% | ||||
| Affimed shareholders | ||||||||||
